Urol. praxi, 2012; 13(3): 101-110

Innovation in the treatment of castration - resistant prostate cancer

MUDr.Otakar Čapoun
Urologická klinika VFN a 1. LF UK v Praze

Prostate cancer is one of the most serious topics of current urology. Up to 20 % of patients reach a phase resistant to antiandrogen therapy

despite castration levels of testosterone. Docetaxel-based cytotoxic therapy then follows in the first line, with further progression new

drugs are available, however their price often exceeds an expected benefit with regards to the prolongation of the overall survival. The

patients have the opportunity to enter numerous clinical trials, however the participation in these protocols can be very demanding.

The aim of the management of castration-resistant prostate cancer must be to ensure an adequate quality of life, pain reduction and

increase of patients’ self-sufficiency. The review article deals with the epidemiological data regarding the last stage of this malignancy,

new hormonal drugs, cytotoxic regimens and immunotherapy, as well as socio-economic and ethical aspects of the treatment of this

very challenging disease.

Keywords: castration-resistant prostate cancer, chemotherapy, abiraterone, quality of life

Published: June 4, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Čapoun O. Innovation in the treatment of castration - resistant prostate cancer. Urol. praxi. 2012;13(3):101-110.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Mottet N, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2011; 59(4): 572-583. Go to original source... Go to PubMed...
    2. Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011; 65(11): 1180-1192. Go to original source... Go to PubMed...
    3. Altekruse SF, Kosary CL, Krapcho M, et al. SEER cancer statistics review, 1975-2007, Bethesda, MD: National Cancer Institute.
    4. Smith MR, Kabbinavar F, Saad F, et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 2005; 23: 2918-2925. Go to original source... Go to PubMed...
    5. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351(15): 1502-1512. Go to original source... Go to PubMed...
    6. Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 2003; 21(7): 1232-1237. Go to original source... Go to PubMed...
    7. Rajpar S, Massard C, Laplanche A, et al. Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer. Ann Oncol. 2010; 21(9): 1864-1869. Go to original source... Go to PubMed...
    8. Armstrong AJ, Garrett-Mayer E, Ou Yang YC, et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol. 2007; 25(25): 3965-3970. Go to original source... Go to PubMed...
    9. Eymard JC, Oudard S, Gravis G. Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study. BJU Int. 2010; 106(7): 974-978. Go to original source... Go to PubMed...
    10. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010; 376(9747): 1147-1154. Go to original source... Go to PubMed...
    11. Shigeta K, Miura Y, Naito Y, et al. Cabazitaxel for castrationresistant prostate cancer. Lancet. 2011; 377(9760): 121. Go to original source... Go to PubMed...
    12. Potter GA, Barrie SE, Jarman M, et al. Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer. J Med Chem. 1995; 38(13): 2463-2471. Go to original source... Go to PubMed...
    13. O'Donnell A, Judson I, Dowsett M, et al. Hormonal impact of the 17alpha-hydroxylase/C (17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer. 2004; 90(12): 2317-2325. Go to original source... Go to PubMed...
    14. Danila DC, Morris MJ, de Bono JS, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol. 2010; 28(9): 1496-1501. Go to original source... Go to PubMed...
    15. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011; 364(21): 1995-2005. Go to original source... Go to PubMed...
    16. Drecier R, Angus DB, MacVicar GR, et al. Safety, pharmacokinetics, and efficacy of TAK-700 in castration-resistant metastatic prostate cancer: a phase I/II open label study. Genitourin Cancer Symp Proc 2010; 89: abstract 103. Go to original source...
    17. Tran C, Ouk S, Clegg NJ, et al. Development of a secondgeneration antiandrogen for treatment of advanced prostate cancer. Science. 2009; 324(5928): 787-790. Go to original source... Go to PubMed...
    18. Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010; 375(9724): 1437-1446. Go to original source... Go to PubMed...
    19. Medivation and Astellas announce positive survival data from interim analysis of phase 3 AFFIRM trial of MDV3100 in men with advanced prostate cancer. San Francisco, CA: Medivation and Astellas; November 3, 2011. http://www.astellas.us/docs/us/AFFIRM_IA_Press_Release_11-2-11_final.pdf.
    20. Djavan B. Editorial - immunotherapy for prostate cancer. Can J Urol. 2011; 18(4): 5763.
    21. Drake, CG. Prostate cancer as a model for tumour immunotherapy. Nat Rev Imm 2010; 10: 580-593. Go to original source... Go to PubMed...
    22. Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009; 115(16): 3670-3679. Go to original source... Go to PubMed...
    23. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010; 363(5): 411-422. Go to original source... Go to PubMed...
    24. Huber ML, Haynes L, Parker C, et al. Interdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer. J Natl Cancer Inst. 2012 (v tisku). Go to original source... Go to PubMed...
    25. Higano CS, Saad F, Curti BD, et al. A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC). Abstract presented at: American Society for Clinical Oncology Genitourinary Cancers Symposium; February 26-28, 2009; Orlando, FL, USA. Abstract LBA150.
    26. Small EJ. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC). Abstract presented at: American Society for Clinical Oncology Genitourinary Cancers Symposium; February 26-28, 2009; Orlando, FL, USA. Abstract 7.
    27. Slovin SF, Beer TM, Higano CS, et al. Initial phase II experience of ipilimumab alone and in combination with radiotherapy in patients with metastatic castration-resistant prostate cancer abstract 5138. J Clin Oncol 2009; 27: 15 s. Go to original source...
    28. Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer [Clinical Trials.gov identifier NCT01057810]. US National Institutes of Health. http://clinicaltrials.gov. Stav ke dni 23. 1. 2012.
    29. Shah GD, Loizos N, Youssoufian H, et al. Rationale for the development of IMC-3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet-derived growth factor receptor alpha. Cancer. 2010; 116(Suppl 4): 1018-2106. Go to original source... Go to PubMed...
    30. Clinical Trial Protocol: IMCL CP15-00805 Version 2.0. ImClone LLC. 28 September 2010.
    31. Dahut WL, Gulley JL, Arlen PM, et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol. 2004; 22(13): 2532-2539. Go to original source... Go to PubMed...
    32. Stokes ME, Ishak J, Proskorovsky I, et al. Lifetime Economic Burden of Prostate Cancer. BMC Health Serv Res. 2011; 11(1): 349. Go to original source... Go to PubMed...
    33. Krahn MD, Zagorski B, Laporte A, et al. Healthcare costs associated with prostate cancer: estimates from a population-based study. BJU Int. 2010; 105(3): 338-346. Go to original source... Go to PubMed...
    34. Zaghloul HA, Murillo JR Jr. Treatment Given Near the End of Life in Castration-Resistant Prostate Cancer. Am J Hosp Palliat Care. 2012 (v tisku). Go to original source... Go to PubMed...
    35. Elting LS, Cooksley C, Bekele BN, et al. Generalizability of cancer clinical trial results: prognostic differences between participants and nonparticipants. Cancer. 2006; 106(11): 2452-2458. Go to original source... Go to PubMed...
    36. Abdulla A, Kapoor A. Emerging novel therapies in the treatment of castrate-resistant prostate cancer. Can Urol Assoc J. 2011; 5(2): 120-133. Go to original source... Go to PubMed...
    37. Agarwal N, Sonpavde G, Sternberg CN. Novel Molecular Targets for the Therapy of Castration-Resistant Prostate Cancer. Eur Urol. 2011 Dec 22 (v tisku). Go to original source...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.